Compare Dover Corp (DOV) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Dover Corp trades at $190.16 (market cap $25.36B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.1× Dover Corp's market cap, and Dover Corp pays a 1.12% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DOV | VRTX | |
|---|---|---|
Market Cap | $25.36B | $128.16B |
Volume | 661,752 | 806,603 |
Sector | Industrials | Health |
52-Week High | $233.31 | $557.96 |
52-Week Low | $161.16 | $407.37 |
Typical Hold Time | 73 Days | 120 Days |
Enterprise Value | $26.86B | $122.29B |
Dividend Yield | 1.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOV trades at $188.96, down 1.52% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company maintains strong profitability with a net income margin of 13.48% and has beaten earnings estimates for three consecutive quarters. Recent news highlights product launches and strategic acquisitions, including the completion of the Cloeren acquisition in August 2026, supporting growth initiatives.
Analyst consensus is strongly bullish with a $243.20 price target, implying significant upside. Key risks include execution of acquisitions and macroeconomic pressures on industrial demand. The stock's valuation multiples appear reasonable relative to earnings growth, positioning it for potential recovery if operational momentum continues.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
